Evidence map›Paper›PMID 39079813›Full record

ArticleVaccine2024

Pre-existing immunity to influenza aids ferrets in developing stronger and broader H3 vaccine-induced antibody responses.

Yang Ge, Yao Lu, James D Allen, Tal Einav, Dennis I Nkaleke, Fengwei Bai, Andreas Handel, Ted M Ross, Ye Shen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yang GeSchool of Health Professions, University of Southern Mississippi, Hattiesburg 39402, MS, USA.
Yao LuDepartment of Epidemiology and Biostatistics, College of Public Health, University of Georgia, Athens 30602, GA, USA.
James D AllenCleveland Clinic, Florida Research and Innovation Center, Cleveland Clinic, Port St. Lucie, FL 34987, USA.
Tal EinavCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA; Department of Medicine, University of California San Diego, La Jolla, CA 92037, USA.
Dennis I NkalekeSchool of Health Professions, University of Southern Mississippi, Hattiesburg 39402, MS, USA.
Fengwei BaiSchool of Biological, Environmental, and Earth Sciences, University of Southern Mississippi, Hattiesburg 39402, MS, USA.
Andreas HandelDepartment of Epidemiology and Biostatistics, College of Public Health, University of Georgia, Athens 30602, GA, USA.
Ted M RossCleveland Clinic, Florida Research and Innovation Center, Cleveland Clinic, Port St. Lucie, FL 34987, USA; Center for Vaccines and Immunology, The University of Georgia, Athens 30606, GA, USA; Cleveland Clinic, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44106, USA.
Ye ShenDepartment of Epidemiology and Biostatistics, College of Public Health, University of Georgia, Athens 30602, GA, USA. Electronic address: yeshen@uga.edu.

Funding

COVID Supplement - COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES,75N93019C00052 · NIAID · UNIVERSITY OF GEORGIA · PI ROSS, TED · 2019 to 2025
$74.6M
Drivers of individual variation in influenza vaccine response and protection from infectionR01AI170116 · NIAID · UNIVERSITY OF CHICAGO · PI Sarah Cobey, John S Tsang · 2022 to 2026
$7.2M
Refining Predictive Models for Neglected and Emerging Infectious DiseasesR35GM146612 · NIGMS · UNIVERSITY OF GEORGIA · PI Ye Shen · 2022 to 2026
$1.9M
NIAID NIH HHS 75N93019C00052NIAID NIH HHS R01 AI170116NIGMS NIH HHS R35 GM146612
6 · The paper itself

Abstract

Influenza seasons occur annually, building immune history for individuals, but the influence of this history on subsequent influenza vaccine protection remains unclear. We extracted data from an animal trial to study its potential impact. The trial involved 80 ferrets, each receiving either one type of infection or a placebo before vaccination. We quantified the vaccine protection by evaluating hemagglutination inhibition (HAI) antibody titer responses. We tested whether hosts with different infection histories exhibited similar level of responses when receiving the same vaccine for all homologous and heterologous outcomes. We observed that different pre-existing immunities were generally beneficial to vaccine induced responses, but varied in magnitude. Without pre-immunity, post-vaccination HAI titers after the 1st dose of the vaccine were less likely to be above 1:40, and a booster shot was needed. Our study suggests that pre-existing immunity may strengthen and extend the homologous and heterologous vaccine responses.

Indexed as

Antibodies, ViralFerretsHemagglutination Inhibition TestsInfluenza VaccinesOrthomyxoviridae InfectionsAnimalsAntibody FormationFemaleMaleVaccinationAntibodies, ViralInfluenza VaccinesCross-protectionFerretHemagglutination inhibition (HAI) assayInfection historyInfluenzaPre-existing immunityVaccine

Identifiers

PMID39079813
PMCPMC11380186

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.